Tango Therapeutics (TNGX) Cash & Current Investments (2020 - 2026)

Tango Therapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $379.8 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 75.26% year-over-year to $379.8 million; the TTM figure through Mar 2026 stood at $379.8 million (up 75.26% YoY), while the FY2025 annual figure was $112.7 million, down 56.73% from the prior year.
• Cash & Current Investments was $379.8 million for Q1 2026 at Tango Therapeutics, up from $112.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $449.9 million in Q1 2022 to a low of $59.4 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $206.2 million across 5 years, with a median of $180.8 million in 2025.
• Biggest YoY gain for Cash & Current Investments was 583.81% in 2022; the steepest drop was 79.98% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $60.5 million in 2022, then climbed by 11.15% to $67.3 million in 2023, then jumped by 287.14% to $260.5 million in 2024, then sank by 56.73% to $112.7 million in 2025, then surged by 237.01% to $379.8 million in 2026.
• The last three Cash & Current Investments figures came in at $379.8 million (Q1 2026), $112.7 million (Q4 2025), and $152.8 million (Q3 2025), per Business Quant data.